Chih Ming Chen
Directeur Général chez TWI PHARMACEUTICALS INC
Profil
Chih Ming Chen is the founder of TWi Pharmaceuticals, Inc. (founded in 1997) and TWi Biotechnology, Inc. (founded in 2010).
He holds the title of Chairman & Chief Executive Officer at TWi Pharmaceuticals, Inc. and Chairman at TWi Biotechnology, Inc. Dr. Chen is also the founder of Allgenesis Biotherapeutics, Inc. Dr. Chen's current jobs include Director positions at TWi Pharmaceuticals Holding, Inc., Eldridge Capital Group Ltd., and Delightful Cheers Ltd.
Dr. Chen's former job was as Chairman of Jiachen International Pharmaceutical Co., Ltd.
Dr. Chen's education includes a doctorate degree from The Ohio State University (conferred in 1981), an undergraduate degree from National Taiwan University (conferred in 1974), and a graduate degree from National Taiwan University (conferred in 1976).
Postes actifs de Chih Ming Chen
| Sociétés | Poste | Début |
|---|---|---|
| TWI PHARMACEUTICALS INC | Directeur Général | 01/12/1997 |
TWi Pharmaceuticals Holding, Inc.
 TWi Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services. | Directeur/Membre du Conseil | - |
| Delightful Cheers Ltd. | Directeur/Membre du Conseil | - |
| Eldridge Capital Group Ltd. | Directeur/Membre du Conseil | - |
Allgenesis Biotherapeutics, Inc.
 Allgenesis Biotherapeutics, Inc. BiotechnologyHealth Technology Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014. | Fondateur | - |
Anciens postes connus de Chih Ming Chen
| Sociétés | Poste | Fin |
|---|---|---|
Jiachen International Pharmaceutical Co., Ltd.
 Jiachen International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Jiachen International Pharmaceutical Co., Ltd. engages in the investment, biotechnology service and management consulting industries. The company was founded on February 15, 2019 and is headquartered in Taipei, Taiwan. | Président | - |
| TWI BIOTECHNOLOGY, INC. | Fondateur | - |
Formation de Chih Ming Chen
| The Ohio State University | Doctorate Degree |
| National Taiwan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TWI BIOTECHNOLOGY, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
TWi Pharmaceuticals, Inc.
 TWi Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals, Inc. operates as a technology-based special pharmaceutical company. The firm engages in the development and commercialization of high barrier generics drugs. Its products include donepezil hydrochloride tablets, megestrol acetate oral suspension, hydroquinone cream, guanfacine extended-release tablets and nifedipine extended-release tablets. The company was founded by Chih Ming Chen on December 1, 1997 and is headquartered in Taipei, Taiwan. | Health Technology |
TWi Pharmaceuticals Holding, Inc.
TWi Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services. | Health Technology |
| Eldridge Capital Group Ltd. | |
Allgenesis Biotherapeutics, Inc.
Allgenesis Biotherapeutics, Inc. BiotechnologyHealth Technology Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014. | Health Technology |
Jiachen International Pharmaceutical Co., Ltd.
Jiachen International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Jiachen International Pharmaceutical Co., Ltd. engages in the investment, biotechnology service and management consulting industries. The company was founded on February 15, 2019 and is headquartered in Taipei, Taiwan. | Health Technology |
| Delightful Cheers Ltd. |
